“One of the biggest problems in the treatment of depression today is a delay in onset of therapeutic effects”
More than 1 in 10 Americans take antidepressants, but these medications can take weeks—and for some patients, months—before they begin to alleviate symptoms. Now, scientists from the University of Chicago have discovered that selectively blocking a serotonin receptor subtype induces fast-acting antidepressant effects in mice, indicating a potential new class of therapeutics for depression. The work was published Oct. 29 in Molecular Psychiatry.
“One of the biggest problems in the treatment of depression today is a delay in onset of therapeutic effects. There has been a great need to discover faster-acting drugs,” said Stephanie Dulawa, PhD, associate professor of psychiatry and behavioral neuroscience at the University of Chicago and senior author of the study.
Delayed onset of antidepressant therapeutics can significantly impact patients, especially those with major depressive disorder, who often spend months switching between ineffective medications. Currently, only two drugs—ketamine and scopolamine—exhibit rapid onset. Due to severe side effects, however, neither is suitable for human use.
In seeking a new class of fast-acting therapeutics, Dulawa and her team tested biological pathways that had previously been shown to generate antidepressant effects but had never been studied for rate of onset. They looked at different subtypes of serotonin receptors, proteins that are binding partners for serotonin, a neurotransmitter that has been shown to regulate mood, memory and appetite.
Of these subtypes, serotonin 2C receptors stood out. Selectively blocking these receptors in mice significantly reduced depression-like behaviors in only five days, compared to a minimum of two weeks for a control antidepressant medication.
“We observed fast-acting therapeutic effects in multiple behavioral tasks after we administered compounds that selectively block serotonin 2C receptors,” said Mark Opal, a graduate student at the University of Chicago and lead author of the paper. “We began our measurements at five days, but we think there’s a possibility it could be effective even sooner than that.”
Serotonin 2C receptors normally inhibit the release of dopamine, another neurotransmitter commonly associated with mood, from certain neurons. When 2C is blocked, the researchers believe, more dopamine is released into regions of the brain such as the prefrontal cortex. The team also observed the induction of biomarkers that indicate antidepressant action.
This is the first new biological mechanism that has shown the ability to rapidly alleviate symptoms of depression since ketamine and scopolamine, and it potentially represents a much safer alternative.
Go deeper with Bing News on:
Fast-Acting Antidepressant
- Depression News
Air Pollution and Depression Linked With Heart Disease Deaths in Middle-Aged Adults Apr. 26, 2024 — A study in more than 3,000 US counties, with 315 million residents, has suggested that air ...
- Tackling Treatment Resistant Depression with Multiple Tools
Ketamine changed lives and opened minds to alternative treatments for mental health. But it's no panacea. We're just as excited about these emerging and re-emerging treatments.
- LSD — Yes, LSD — Shows Promising Results For Treating Anxiety
A new study shows that LSD is highly effective at treating generalized anxiety disorder for up to 12 weeks with just a single dose. And it is fast-acting.
- Opinion: Can Ketamine Be Safely Used at Home?
Ketabon is working to develop a medication that harnesses ketamine’s antidepressant effects without the safety issues that currently prohibit its at-home use.
- Treatment of Antidepressant-Induced Sexual Dysfunction
A variety of antidotes have been reported to treat SSRI-induced sexual dysfunction effectively; however, virtually all the data on these agents are derived from open case reports and case series ...
Go deeper with Google Headlines on:
Fast-Acting Antidepressant
[google_news title=”” keyword=”Fast-Acting Antidepressant” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Antidepressants
- Could This Toad’s Psychedelic Venom Be The Next Big Thing In Antidepressants?
B ehold the Colorado River toad. Also known as the Sonoran Desert toad, these bulbous fellas pack a psychedelic punch just below the surface. Their venom, which they can secrete through glands on ...
- Ketamine, Psychotherapy, and Interactions With Medicines
What I want my patients to know about ketamine-assisted psychotherapy, interactions with other medications, and the proper dose.
- The FAA expands the list of approved drugs for pilots
At the start of April, the Federal Aviation Administration (FAA) published a 169-page report on the issue of pilot mental health. Recommendations to improve it include everything from creating better ...
- Woman, 23, was ‘cooked from the inside out’ after taking antidepressants
A WOMAN says she was “cooked from the inside out” after taking antidepressants. Charlotte Gilmour suffered a severe reaction to lamotrigine – used to treat epilepsy and low mood ...
- ‘I’m relying on antidepressants to get through life (and so are most women I know)’
I felt low constantly, and overwhelmed by the enormity of it all. After weeks of sleeplessness, I rang the doctor and asked if maybe, perhaps, some antidepressants would help. She was reluctant to ...
Go deeper with Google Headlines on:
Antidepressants
[google_news title=”” keyword=”antidepressants” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]